Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Disruption of mutated BRAF signaling modulates thyroid cancer phenotype.

BMC research notes - 28 Mar 2014

Hanly Elyse K, Rajoria Shilpi, Darzynkiewicz Zbigniew, Zhao Hong, Suriano Robert, Tuli Neha, George Andrea L, Bednarczyk Robert, Shin Edward J, Geliebter Jan, Tiwari Raj K

Abstract excerpt

BACKGROUND: Thyroid cancer is the most common endocrine-related cancer in the United States and its incidence is rising rapidly. Since among various genetic lesions identified in thyroid cancer, the BRAFV600E mutation is found in 50% of papillary thyroid cancers and 25% of anaplastic thyroid canc...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Carcinoma, Papillary
Share to Indoles
Share to Mitogen-Activated Protein Kinases

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Sulfonamides

Share to Thyroid Cancer, Papillary

Share to Thyroid Carcinoma, Anaplastic

Share to Thyroid Gland

Share to Vemurafenib

Source

Open in PubMed Open full text

Identifiers

PMID: 24673746
DOI: 10.1186/1756-0500-7-187
PMCID: PMC3976539

Genes

BRAF

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026. Prepared record publication-24673746-2026-09-04.2. Manifest publication-graph-cohort-2026-09-04.2.

Source receipt: PubMed via Helena Literature Corpus, retrieved 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Disruption of mutated BRAF signaling modulates thyroid cancer phenotype.PMID 24673746Read ↗

Targeting BRAFV600E with PLX4720 displays potent antimigratory and anti-invasive activity in preclinical models of human thyroid cancer.Semantic proximity Read ↗

Targeting BRAF in thyroid cancer.Semantic proximity Read ↗

Genetic alterations in differentiated thyroid cancers.Semantic proximity Read ↗

Selective growth inhibition in BRAF mutant thyroid cancer by the mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244.Semantic proximity Read ↗

Distinct genetic alterations in the mitogen-activated protein kinase pathway dictate sensitivity of thyroid cancer cells to mitogen-activated protein kinase kinase 1/2 inhibition.Semantic proximity Read ↗

c-Met-mediated reactivation of PI3K/AKT signaling contributes to insensitivity of BRAF(V600E) mutant thyroid cancer to BRAF inhibition.Semantic proximity Read ↗

PD-1 Blockade Delays Tumor Growth by Inhibiting an Intrinsic SHP2/Ras/MAPK Signalling in Thyroid Cancer CellsSemantic proximity Read ↗

Dual targeting of PDPK1 and BRAF V600E is synthetically lethalSemantic proximity Read ↗

Mutationally activated BRAF(V600E) elicits papillary thyroid cancer in the adult mouse.Semantic proximity Read ↗

Role of the ETV5/p38 signaling axis in aggressive thyroid cancer cellsSemantic proximity Read ↗

BRAF inhibitors: experience in thyroid cancer and general review of toxicity.Semantic proximity Read ↗

Inhibition of BRAF and ERK1/2 has synergistic effects on thyroid cancer growth in vitro and in vivo.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.